Dr. Reddy’s Secures License from Henlius to Market Daratumumab Biosimilar in the U.S. and Europe
JD Supra: Mergers
FEBRUARY 17, 2025
On February 6, 2025, Dr, Reddys Laboratories SA (Dr. Reddys) announced that it has entered into a license agreement with Shanghai Henlius Biotech, Inc. (Henlius) for the development and commercialization of Henliuss HLX15 (daratumumab), a biosimilar candidate to Janssens Darzalex & Darzalex Faspro.
Let's personalize your content